{
    "clinical_study": {
        "@rank": "157884", 
        "acronym": "PARADIGM", 
        "arm_group": [
            {
                "arm_group_label": "IDEV SUPERA Stent", 
                "arm_group_type": "Experimental", 
                "description": "Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment."
            }, 
            {
                "arm_group_label": "Percutaneous Transluminal Angioplasty", 
                "arm_group_type": "Active Comparator", 
                "description": "The target lesion will be treated by PTA alone."
            }
        ], 
        "brief_summary": {
            "textblock": "Unblinded, randomized, balanced trial comparing 12 month target lesion patency rates of the\n      IDEV SUPERA VERITAS peripheral stent system to PTA in the treatment of obstructive\n      atherosclerotic popliteal artery disease."
        }, 
        "brief_title": "Popliteal Artery of Treatment With Balloon Angioplasty vs. SUPERA VERITAS Peripheral Stent System", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Vascular Disease.", 
        "condition_browse": {
            "mesh_term": [
                "Vascular Diseases", 
                "Peripheral Vascular Diseases", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has lifestyle limiting claudication or rest pain or at least a single de novo\n             or restenotic popliteal artery lesion.\n\n        Exclusion Criteria:\n\n          -  Inteervention distal to the target lesion is required at the time of the index\n             procedure or within 30 days after the index procedure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "318", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01667393", 
            "org_study_id": "IDEV  POP-01-US/OUS"
        }, 
        "intervention": [
            {
                "arm_group_label": "IDEV SUPERA Stent", 
                "intervention_name": "IDEV SUPERA Stent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Percutaneous Transluminal Angioplasty", 
                "intervention_name": "Percutaneous Transluminal Angioplasty", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 15, 2012", 
        "number_of_arms": "2", 
        "official_title": "Popliteal Artery Trial of Patients Undergoing Treatment With Balloon Angioplasty vs. the Adaptive SUPERA VERITAS Peripheral Stent System", 
        "overall_contact": {
            "email": "cbase@idevmd.com", 
            "last_name": "Carol C Base, BSN, MS", 
            "phone": "281-525-2000"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary efficacy will be target lesion primary patency at 12 months.", 
            "measure": "Primary patency", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01667393"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Major Adverse Event-free survival rate that is non-inferior to that of PTA at 12 months.", 
            "measure": "MAE-free survival rate.", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "IDev Technologies, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IDev Technologies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}